Divided or Single Exposure (DOSE) Study
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Maryland, Baltimore
About this trial
This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.
Eligibility criteria
Qualifiers
Aged 18 years of age or older
Currently receiving methadone for treatment of OUD for >90 days and have been consuming the same dose for >30 days
Have previously received a take-home dose of methadone as part of routine care
Willing to comply with study schedule
Disqualifiers
Pregnant
Presence of acute medical problem that requires immediate and intense medical management
Presence of a serious and unstable mental illness that interferes with provision of voluntary informed consent and/or adherence to study visits
Plans to leave methadone treatment during the study period
Trial design
Treatments tested in this trial
- Methadone (100% dose)
- Methadone (50% dose)
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Maryland, Baltimore
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov